Arrhythmia Research Technology Announces Second Quarter Earnings - 2002.

Business/Technology Editors

FITCHBURG, Mass.--(BUSINESS WIRE)--Aug. 13, 2002

Arrhythmia Research Technology, Inc. ("ART")(AMEX: HRT) reported revenue of $1,832,237 and net income of $101,440 for the second quarter of 2002 compared to revenue of $1,874,662 and net income of $102,652 for the second quarter 2001.

For the six months ended June 30, 2002, revenue was $3,747,334 and net income was $246,461 or $ .08 per share compared to revenue of $3,628,636 and net income of $136,704 or $ .04 per share for the six months ended June 30, 2001. The improvement in net income for the period is attributed to savings in administrative costs and research and development expenses related to closing ART's operations in Austin, Texas in 2001.

                        Second Quarter                Six Months
                     2002          2001          2002           2001
Revenue            1,832,237     1,874,662     3,747,334     3,628,636
Net income           101,440       102,652       246,461       136,704
Net income per
 share (basic
 and dilutive)           .03           .03           .08           .04
Weighted average
shares- basic      2,918,922     3,015,213     2,919,731     3,063,359

In the second quarter of 2002, the Company announced its intention to purchase certain assets of a competitor of Micron Products, Inc., the wholly owned subsidiary of ART. On July 22, the Company announced that the parties had discontinued negotiations of the acquisition. Legal costs of $98,000 ($70,000 net of tax) were incurred in conjunction with the proposed asset purchase and have been expensed in the second quarter of 2002.

Micron sales of standard ECG sensors have increased 5% in the first six months of 2002 compared to 2001, overall sales have increased 3% for the same period. Micron has also received notification that it has been chosen as the new supplier by a major customer for radiotranslucent ECG sensors that could increase Micron's annual sales by approximately 10% beginning in late 2002.

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. These statements are made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks and an inability to arrange additional debt or equity financing.